Conference Proceedings

Phase I/II Study of CYT387, a JAK1/JAK2 Inhibitor for the Treatment of Myelofibrosis

Animesh Pardanani, Jason Gotlib, Vikas Gupta, Andrew W Roberts, Martha Wadleigh, Shireen Sirhan, Linda M Bavisotto, Jun Kawashima, Mark Kowalski, Ayalew Tefferi

BLOOD | AMER SOC HEMATOLOGY | Published : 2012


Abstract Abstract 178 Background: CYT387 is a potent and selective small molecule inhibitor of JAK 1 and JAK 2 which is in clinical development for the treatment of myelofibrosis. Previously reported preliminary results from a phase I/II multicenter study demonstrated improvements in splenomegaly and constitutional symptoms as well as in RBC transfusion requirements. Enrollment has been completed and all subjects have now reached a minimum of 9 months on study. Updated safety and efficacy results are presented. Methods: Subjects with high or intermediate-risk..

View full abstract

University of Melbourne Researchers